Drugs Made In America Acquisition Corp.

DMAA

Explore Our Financial Data > Companies > Drugs Made In America Acquisition Corp.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	DMAA
CIK	0002028614
SIC	6770
Sector	Finance, Insurance, And Real Estate
Industry Category	Trading
Industry Group	Investment Offices

Contact

Address	2 PELICAN DR., FORT LAUDERDALE, FL, 33301
Website	N/A
Phone	954-870-3104
CEO	Lynn Stockwell
Employees	2

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	N/A
Net Income	N/A
Net Income to Common	N/A
EPS	N/A

View All

Balance Sheet

Cash	$1,351.00
Assets	$550,824.00
Liabilities	$795,669.00
Common Equity	$-244,845.00
Liabilities & Equity	$550,824.00

View All

Cash Flow Statement

Net Income	N/A
Cash From Operating Activities	N/A
Cash From Investing Activities	N/A
Cash From Financing Activities	N/A
Change in Cash	N/A

View All

Calculations

NOPAT	N/A
EBITDA	N/A
Price to Earnings	N/A
Price to Book	N/A
ROE	N/A

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Drugs Made in America Acquisition Corp. Announces Advisory Team

Fort Lauderdale, FL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Drugs Made in America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced the formation of an advisory team to lead its effort towards acquiring a well-managed, revenue generating business for the foundation and development of “End to End production, manufacturing and distribution, for the Drugs Made In America Platform”. Under the direction of Lynn Stockwell, Chief Executive Officer of DMAAU, the advisory team will proactivel

Article Link

Drugs Made In America Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing February 25, 2025

Fort Lauderdale, Florida, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that, commencing February 25, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s ordinary shares and rights included in the units. No fractional rights will be issued upon separation of the units and only whole rights will trade. The ordinary shares and rights that are separated will t

Article Link

Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option

Fort Lauderdale, Florida, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that the underwriter of its previously announced initial public offering fully exercised its option to purchase an additional 3,000,000 units at the public offering price of $10.00 per unit, resulting in additional gross proceeds of $30,000,000. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “DMAAU” on January

Article Link

Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering

Fort Lauderdale, FL, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced that it closed its initial public offering of 20,000,000 units at $10.00 per unit. The gross proceeds from the offering were $200 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Global Market ("Nasdaq") under the ticker symbol "DMAAU” on January 28, 2025. Each unit consists of one ord

Article Link

The big winner if OpenAI becomes a for-profit business? Microsoft.

OpenAI is considering transitioning from a nonprofit into a for-profit company, and its deep-pocketed benefactor, Microsoft, has a lot to gain if the ChatGPT developer gets the green light.

Article Link